Fundz
Real-time · AI · Cross-signal

Tilt Biotherapeutics just raised. Here's exactly what to do next.

Who to reach, what to say, and why now — on Tilt Biotherapeutics, plus every funding round, exec hire, and M&A move that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.
✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.
✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.
✕Clay enriches lists you built — No live signal of its own, no who or when.
✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.
Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

TILT Biotherapeutics has raised USD 25.6 million in Series B financing led by the EIC Fund, Lifeline Ventures, TESI, and Stephen Industries. The funding will support Phase 2 trials for TILT-123 in ovarian cancer.

PRIVATEMay 13, 2025•about 1 year ago

Amount Raised

$25.6 Million

Round Type

series b

Helsinki

Investors

Stephen Industries Inc OyFinnish Industry Investment (Tesi)Lifeline VenturesEuropean Innovation Council (Eic) Fund

Description

TILT Biotherapeutics has announced the closure of a USD 25.6 million Series B financing round. This funding will aid the Phase 2 clinical trial of their lead product, TILT-123, in treating patients with platinum-resistant epithelial ovarian cancer. Notable investors include the European Innovation Council Fund, Lifeline Ventures, and Finnish Industry Investment. The company is poised to expand trial sites in the USA this year.

Company Information

Company

Tilt Biotherapeutics

Location

Helsinki, Uusimaa, Finland

About

TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company’s patented TILT® technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T therapies.

Predictive Intelligence
Strategic

ML-powered predictions for Tilt Biotherapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies.

Watching Tilt Biotherapeutics? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan